Regulatory & Policy Intelligence
Strategic monitoring of global regulatory evolution, accelerated approval frameworks and pharmaceutical compliance developments.
Regulatory reform directly influences drug approval timelines, market access dynamics and innovation incentives across major jurisdictions.
China’s Innovative Gene Therapy Approved for Market
June 01, 2026
Profits from Weight-Loss Drugs Fuel a Growing Gray Market: How Can Global Pharmaceutical Regulation Achieve Long-Term Governance?
May 29, 2026
As demand for GLP-1 weight-loss drugs surges worldwide, counterfeit medicines, illegal compounded products, and gray-market supply chains are rapidly expanding.
Compliance Upgrades in Cross-Border Pharmaceutical Trade
May 29, 2026
A Breakthrough in Nebulized Antiviral Therapy: Phase III Progress of Peramivir Inhalation Solution
May 25, 2026
Peramivir inhalation solution enters the key Phase III data analysis stage, highlighting new advances in nebulized antiviral therapy and respiratory targeted drug delivery.
Finerenone Approved for a New Indication in China: 18% Reduction in Heart Failure Events and New Progress in HFpEF Treatment
May 23, 2026
Finerenone has been approved in China for adult heart failure patients with LVEF ≥40%, marking a significant advancement in HFpEF and HFmrEF treatment.
FDA Officially Approves Saphnelo Auto-Injector: SLE Patients May Soon Say Goodbye to Long Infusion Sessions
May 21, 2026
The FDA has officially approved the Saphnelo auto-injector for self-administration, marking a new era of home-based treatment and long-term management for SLE patients.
Which Are the Top JCI-Accredited Hospitals in China for International Patients?
May 12, 2026
China’s First IL-1β Monoclonal Antibody Approved: Firsekibart Brings New Breakthrough to Gout Treatment
May 08, 2026
China approves its first IL-1β monoclonal antibody Firsekibart for acute gouty arthritis, marking a breakthrough in precision-targeted anti-inflammatory therapy.
Innovative Drugs Driven by Policy and Clinical Progress
May 08, 2026
China’s innovative drugs sector continues to accelerate under policy support, clinical progress, and global collaboration, reshaping the international pharmaceutical landscape.
Complete Guide for Early Cancer Screening｜A Review of Screening Methods for 6 Common Cancers
May 07, 2026
A comprehensive guide to early cancer screening methods, high-risk populations, and recommended screening intervals for six common cancers.
Global Pharmaceutical Market Under Policy Influence: Reshaping the Landscape and Future Opportunities
May 07, 2026
How pharmaceutical policies are reshaping the global market, influencing innovation, pricing, compliance, and future opportunities in the healthcare industry.
cadonilimab in pancreatic cancer: immunotherapy breakthrough at aacr 2026
May 06, 2026
Proposed Breakthrough Therapy Designation: Keymed’s CM336 Poised to Reshape the Treatment Landscape of AL Amyloidosis
May 06, 2026
Targeting TL1A in Immune-Mediated Inflammatory Diseases: From an Inflammatory Amplifier to a New Strategy for Precision Intervention
April 30, 2026
From R&D to Accessibility: Innovative Medicines Empower the Upgrade of Global Health Systems
April 28, 2026
Innovative medicines are reshaping global health systems, but accessibility remains a key challenge. Exploring the full pathway from R&D to patient access.
China’s First Original Radiopharmaceutical Approved: 99mTc-Pexidartide (Giluntai) Enables Precision Lung Cancer Diagnosis
April 21, 2026
China approves its first Class 1 original radiopharmaceutical 99mTc-Pexidartide (Giluntai), marking a breakthrough in lung cancer lymph node metastasis diagnosis and molecular imaging.
Covering Nearly 20 Rare Diseases: A Comprehensive Overview of Newly Approved Rare Disease Drugs Worldwide in March 2026
April 16, 2026
A comprehensive review of nearly 20 newly approved rare disease drugs worldwide in March 2026, covering hematology, oncology, metabolic disorders, and gene therapy.
2026 Global Innovative Drug R&D and Regulatory Dynamics: ADC and Gene Therapies Lead a New Era
April 10, 2026
In 2026, global innovative drug R&D continues to accelerate, with Antibody-Drug Conjugates (ADCs) and gene therapies taking center stage. This article deeply analyzes the latest approval dynamics from the FDA and NMPA, and explores how these cutting-edge technologies are reshaping the landscape of oncology and rare disease treatments.
Global Pharmaceutical Innovation and Regulatory Dynamics in 2026: Breakthroughs in Oncology and Rare Diseases
April 09, 2026
Why β₁-Selective Beta-Blockers Remain Important in Cardiovascular Therapy
March 30, 2026
Explore why β₁-selective beta-blockers like bisoprolol remain essential in cardiovascular therapy, with improved safety and targeted mechanisms.